MediPharm Labs has signed a definitive supply agreement with Remidose Aerosols for the shipment of GMP-certified medicinal cannabis products to Costa Rica.
"MediPharm Labs' proven ability to navigate complex regulatory environments enables us to deliver GMP-certified cannabinoid products to highly regulated markets worldwide," says David Pidduck, CEO of MediPharm Labs. "This agreement strengthens our commitment to supporting medical patients in Costa Rica and advancing international access to quality cannabis solutions."
Costa Rica's medical cannabis market officially opened to regulated sales in June 2025 and is projected to exceed 35 million USD annually, driven by strong patient demand and a comprehensive regulatory framework focused on product safety and GMP compliance.1
"Remidose LATAM is proud to be fully licensed and authorized by Costa Rican health authorities to import medicinal cannabis products. Partnering with MediPharm Labs allows us to offer patients access to some of the highest quality, GMP-certified cannabis products available globally. MediPharm's standards, reliability and proven ability to deliver in regulated markets make them the ideal partner for our mission to improve patient care in Costa Rica," commented Michael Mayne, President of Remidose.
For more information:
MediPharm Labs
medipharmlabs.com
